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Human Immunodeficiency Virus- (HIV-) infected persons have a higher risk for acute myocardial infarction (AMI) than HIV-
uninfected persons. Earlier studies suggest that HIV viral load, CD4+ T-cell count, and antiretroviral therapy are associated with
cardiovascular disease (CVD) risk. Whether CD8+ T-cell count is associated with CVD risk is not clear. We investigated the
association between CD8+ T-cell count and incident AMI in a cohort of 73,398 people (of which 97.3% were men) enrolled in
the U.S. Veterans Aging Cohort Study-Virtual Cohort (VACS-VC). Compared to uninfected people, HIV-infected people with high
baseline CD8+ T-cell counts (>1065 cells/mm3) had increasedAMI risk (adjustedHR = 1.82, 𝑃 < 0.001, 95%CI: 1.46 to 2.28).There
was evidence that the effect of CD8+ T-cell tertiles on AMI risk differed by CD4+ T-cell level: compared to uninfected people, HIV-
infected people with CD4+ T-cell counts ≥200 cells/mm3 had increased AMI risk with high CD8+ T-cell count, while those with
CD4+ T-cell counts <200 cells/mm3 had increased AMI risk with low CD8+ T-cell count. CD8+ T-cell counts may add additional
AMI risk stratification information beyond that provided by CD4+ T-cell counts alone.
1. Introduction
Human Immunodeficiency Virus- (HIV-) infected persons
have a higher risk for acutemyocardial infarction (AMI) than
HIV-uninfected persons [1, 2]. This excess risk is predicted
in part by immune status in those with HIV infection [1,
3, 4]. During the course of untreated HIV infection, CD4+
T-cell counts decline. Among untreated and treated HIV-
infected adults, lower CD4+ T-cell counts are associated with
greater risk of comorbid disease [5] including AMI risk or
subclinical coronary atherosclerosis [1, 3, 4, 6, 7]. Traditional
cardiovascular disease (CVD) risk assessment tools like the
Framingham Risk scores do not account for immune status
and therefore may inaccurately estimate CVD risk in the set-
ting of HIV [8]. Identifying additional prognostic biomarkers
of CVD risk may be useful for CVD risk prediction in the
setting of HIV.
The association between CD8+ T-cell counts and incident
AMI risk remains largely unexplored [4]. In a nested case-
control study of the French Hospital Database on HIV [4],
Lang and colleagues found that a high current CD8+ T-cell
count is associated with increased AMI risk, independent of
cardiovascular risk factors and antiretroviral therapy. This
study did not have an HIV-uninfected control group and
did not consider additional potential confounders, such as
hemoglobin concentration, renal function, and hepatitis C
viral infection.
Total CD8+ T-cell counts are often obtained during
routine care of HIV-infected persons and are used in the
calculation of a CD4+/CD8+ T-cell ratio, which provides
information on immune status beyond CD4+ counts alone.
We assessed the association between routinely available total
CD8+ T-cell count and the risk of AMI in a large cohort
of HIV-infected and HIV-uninfected persons, adjusting for
common traditional cardiovascular risk factors as well as
HIV-specific parameters.
2. Materials and Methods
We examined the association between CD8+ T-cells and AMI
risk among 73,398 persons enrolled in the U.S. Veterans
AgingCohort Study-Virtual Cohort (VACS-VC) [9]whowere
free of cardiovascular disease at baseline date (April 2003).
Participants were followed through December 2009 for a
mean follow-up period of 4.98 years. Details regarding this
cohort have been published previously [1]. Among HIV-
infected participants, 18,289 had available baseline CD8+
data at the time of enrollment of which 16,599 had both
CD4+ and CD8+ data. There were 55,109 HIV-uninfected
participants.The mean (±SD) age was approximately 48 (±9)
years (HIV-infected) and 49 (±9) years (HIV-uninfected).
Over 97 percent were men and 48 percent were African
American.The outcome of interest was all incident AMI cases
(nonfatal and fatal) in the VACS-VC that were completely
managed in either VA or non-VA hospitals as previously
described [1]. Briefly, incidentAMIwas definedusing enzyme
data, EKG charts, clinical data, 410 in-patient ICD-9 codes
(Medicare), and/or death certificates.
The main independent variable of interest was the base-
line total CD8+ T-cell count, which was analyzed separately
as a continuous variable and categorically. CD8+ T-cell
counts were available only for HIV-seropositive Veterans
as they were obtained as part of routine clinical care. For
the assessment as a continuous variable, the CD8+ T-cell
count analysis was restricted to HIV-infected participants.
As a categorical variable, study participants were classified
as being either HIV-uninfected (the referent group) or HIV-
infectedwith low,moderate, or high total CD8+ T-cells (based
on tertiles). Using the same referent group, we then stratified
these categories among HIV-infected people by baseline
CD4+ T-cell count (≥500, 200–499, and <200 cells/mm3).
The covariates included in themultivariablemodels were age,
gender, race, high blood pressure (controlled/uncontrolled),
diabetes, triglyceride levels, high density lipoprotein levels,
low density lipoprotein levels, bodymass index, smoking his-
tory, hepatitis C virus infection, estimated glomerular filtra-
tion rate, statin use, hemoglobin concentration, cocaine and
alcohol abuse, and/or dependence as previously described
[1]. We included missing covariate data in our analyses using
multiple imputation techniques that generated five data sets
with complete covariate values to increase the efficiency and
robustness of the estimated hazard ratios. Stata version 12 was
used for all statistical analyses and a 𝑃 value of <0.05 was
considered to indicate statistical significance.
3. Results and Discussion
Survival free from AMI was different among HIV-
uninfected and the three tertiles of HIV-infected people (𝑃
value <0.001, Figure 1). The poorest survival free of AMI
was observed among those in the highest CD8+ T-cell
tertile (>1065 cells/mm3). Increasing CD8+ T-cell counts
were associated with a modest increase in AMI risk among
HIV-infected people (HR per 100 CD8+ T-cells (95%CI): 1.03
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Figure 1: Graph of Kaplan-Meier survival estimates of AMI devel-
opment for differentHIV/CD8+ T-cell strata. Abbreviations used are
HIV−, HIV-uninfected, HIV+, HIV-infected. All T-cell counts in
cells/mm3. Difference in survival function equality based onTarone-
Ware and Peto-Peto-Prentice tests had a 𝑃 value <0.001, 𝑑𝑓 = 3.
(1.01–1.05); Table 1). Compared to uninfected participants,
HIV-infected participants in all tertiles of CD8+ T-cell
count had a significantly increased risk of AMI. There was a
stepwise increase in AMI risk with increasing CD8+ T-cell
count with the highest risk in the highest CD8+ T-cell tertile
(>1065 cells/mm3; HR = 1.82, 95% CI: 1.46–2.28; Table 1).
We found evidence that the effect of CD8+ T-cell tertiles
on AMI risk differed by CD4+ T-cell level. Compared to
uninfected people, HIV-infection with a high CD8+ T-cell
count was associated with AMI among those with CD4+
T-cell counts ≥200 cells/mm3 while a low CD8+ T-cell count
was associated with a higher risk of AMI among those with
CD4+ T-cell counts <200 cells/mm3 (Table 1). The stepwise
increase in AMI risk with increasing CD8+ T-cell count was
most extreme among HIV-infected people with CD4+ T-cell
counts between 200 and 499 cells/mm3 (Table 1).
In summary, while increasing CD8+ T-cell count was
associatedwith increasing risk of AMI, stratification byCD4+
T-cell count unmasked potentially important associations:
higher CD8+ T-cell counts are associated with AMI risk in
those with CD4+ T-cell counts ≥200 cells/mm3 while lower
CD8+ T-cell counts are associated with AMI risk in those
with low CD4+ T-cell counts. Second, the impact of a high
versus low CD8+ T-cell count was most evident in those
individuals with CD4+ T-cell counts of 200–499 cells/mm3.
Importantly, all-cause mortality rates were similar across all
three CD8+ T-cell tertiles among those with CD4+ T-cell
counts ≥200 cells/mm3.
Among participants for whom high CD8+ T-cell counts
predicted AMI (i.e., CD4+ T-cell count ≥200 cells/mm3), it
is possible that activation of the large numbers of CD8+ T-
cells may contribute to vascular damage [10]. In contrast,
our finding that HIV-infected Veterans with a low CD4+ T-
cell level appeared to be at greatest AMI risk when their
CD8+ T-cell count was also low is consistent with earlier
work suggesting that AMI risk is linked to immunodeficiency
[1, 3]. Decline in both CD4+ and CD8+ T-cell counts is a
manifestation of very advanced disease and likely reflects
loss of regenerative potential (e.g., loss of hematopoietic
stem cells) [11]. Moreover, decline of the adaptive immune
system may increase innate immune activity, which could
also increase AMI risk [12].
The study had limitations. First, we did not explore
changes in HIV-specific CD8+ T-cell counts nor did we
examine markers for CD8+ T-cell immune activation, such
as CD38+. Time-updated covariates for CD8+ (and CD4+)
T-cells were not used to determine AMI risk. Third, over
90% of the participants were men (∼89% were men in the
study by Lang et al. [4]), so the study results may not be
generalizable to women. All-cause mortality rates were high-
est among those with CD4+ T-cell counts <200 cells/mm3;
therefore AMI risk may be underestimated due to com-
peting risk of death. Finally, our clinical data does not
allow further delineation of T-cell subsets that have been
associated with atherosclerotic (e.g., T helper 1 (TH1) cells)
and antiatherosclerotic processes (e.g., regulatory T helper 2
(TH2) cells) [12].
4. Conclusions
In conclusion, high CD8+ T-cell count among HIV-infected
people was associated with increased acute myocardial
infarction risk compared to uninfected people. The associa-
tion between CD8+ T-cell count and AMI appears to differ
by CD4+ T-cell count. CD8+ T-cell count may add additional
AMI risk stratification information beyond that provided by
CD4+ T-cell counts particularly among those with CD4+ T-
cell counts between 200 and 499 cells/mm3. These findings
should be confirmed in future studies with data on CD8+ T-
cell counts among uninfected people and HIV-specific CD8+
T-cell counts.
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